GlassScriptPhysician profile
Chasidy Dionne Singleton
NPI 1255425260
$7,317.71
in general payments reported to CMS, 2019-2025
29 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $394 · 2021: $1,110 · 2022: $2,045 · 2023: $1,588 · 2024: $915 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,569.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,500.57 | 2020-2025 | Acthar |
| Alcon Vision LLC | $701.47 | 2022-2025 | Luxor, Hydrus Microstent, Unity |
| Allergan, INC. | $551.63 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $546.64 | 2021-2023 | Cequa |
| Abbvie INC. | $455.87 | 2022-2025 | Durysta |
| Sight Sciences, INC. | $415.85 | 2022-2024 | Tearcare System, Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $305.34 | 2020-2021 | |
| Oyster Point Pharma, INC. | $282.27 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $251.79 | 2022-2025 | Miebo, Stellaris, Xiidra |
| Biotissue Holdings INC. | $215.32 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $212.12 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $172.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $172.08 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $170.30 | 2022-2023 | Tecnis Iol |
| Amgen INC. | $169.01 | 2025 | Tepezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $165.16 | 2024-2025 | Dextenza |
| Glaukos Corporation | $156.54 | 2019-2024 | Idose |
| Carl Zeiss Meditec USA, INC. | $147.89 | 2022 | |
| Dompe US, INC. | $141.58 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $123.49 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $101.69 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $83.88 | 2022-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.79 | 2019-2021 | |
| Lkc Technologies, INC. | $59.40 | 2025 | |
| Carl Zeiss Meditec Cataract Technology INC. | $38.88 | 2022 | |
| Eyevance Pharmaceuticals LLC | $36.75 | 2022 | |
| Cormedix INC. | $25.91 | 2024 | Defencath |
| Notal Vision, INC. | $19.49 | 2024 | Foresee Home |
| Astellas Pharma US INC | $18.71 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chasidy Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.